Ipsen inks $80M licensing deal; TiaGen reports Phase II results;

@FierceBiotech: Great article from Xconomy on what's at stake for Lilly, Amylin and Alkermes on the Byetta LAR decision. Article | Follow @FierceBiotech

@JohnCFierce: Murmurs of trouble with Aveo IPO. WSJ mentions shareholders forced pricing delay yesterday, resisting price. Yikes. Report | Follow @JohnCFierce

> Ipsen and Rhythm Pharmaceuticals have concluded a license agreement for Ipsen's peptide therapeutics targeting obesity, metabolic diseases, and gastrointestinal disorders. Under the terms of the license agreement, Ipsen will receive progressive payments of up to $80 million upon the achievement of certain development and commercial milestones and royalties on future sales of the products. Ipsen release

> TaiGen Biotechnology reported its Phase II trial of nemonoxacin (TG-873870) in Diabetic Foot Infection with once-a-day dosing met the primary endpoints and showed promising clinical efficacy and good tolerability. TiaGen release

> Manhattan Pharmaceuticals has completed its merger transaction with Ariston Pharmaceuticals. Ariston became a wholly owned subsidiary of Manhattan Pharmaceuticals. Release

> Progenics Pharmaceuticals announced that will begin a Phase IIb/III trial of a methylnaltrexone tablet in chronic-pain patients in the second half of 2010. Progenics release

> The majority of patients' organizations consider pharmaceutical companies untrustworthy, according to a soon-to-be-released survey conducted by a U.K.-based consultancy. Report

And Finally... Sick of the time changes that daylight savings require? You're not alone. Report

Suggested Articles

Genor Biopharma banked $160 million from the likes of Hillhouse and Temasek Holdings to advance its clinical-stage autoimmune and cancer programs.

Going from being the CSO of Bristol Myers Squibb to running one of the biggest cancer research organizations in the world is a major career shift.

Hahn made the commitment in a speech that called on the FDA to learn from the crisis to enact lasting policies that accelerate drug development.